ReviewCureus2025
Outcomes of Antithrombotic Therapy in Patients Undergoing Gastrointestinal Surgery: A Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety in Spine Surgery: Risk Factors for Intraoperative Blood Loss and Management Strategies.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antithrombotic therapy is commonly prescribed for the prevention and management of thromboembolic diseases but poses significant challenges in the perioperative setting of gastrointestinal (GI) surgery due to the competing risks of bleeding and thrombosis. This meta-analysis aimed to evaluate the clinical outcomes associated with perioperative antithrombotic therapy in patients undergoing GI surgery. A systematic search was conducted in PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, ProQuest, and Google Scholar, following Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Nine studies comprising 13,107 patients were included. The primary outcomes assessed were postoperative bleeding, thromboembolic events, and blood transfusion requirements. Statistical analysis was performed using a DerSimonian-Laird random-effects model, and outcomes were reported as odds ratios (ORs) with 95% confidence intervals (CIs). The pooled analysis showed a non-significant trend toward increased postoperative bleeding in patients on antithrombotic therapy (OR: 1.64, 95% CI: 0.98-2.75, p = 0.061). Thromboembolic events did not differ significantly between groups (OR: 0.91, 95% CI: 0.41-2.04, p = 0.82), with low heterogeneity (I² = 0%). However, transfusion requirements were significantly higher in the antithrombotic group (OR: 2.87, 95% CI: 1.19-6.95, p = 0.019), indicating an increased need for intraoperative or postoperative blood products. While continuation of aspirin monotherapy appeared relatively safe in elective settings, dual antiplatelet therapy and direct oral anticoagulants (DOACs) were associated with greater bleeding risks, particularly in complex or minimally invasive procedures. These findings suggest that with careful patient selection and perioperative planning, antithrombotic therapy can often be safely managed during GI surgery. However, individualized risk assessment remains critical to minimize adverse outcomes. Further randomized controlled trials are needed to establish clear guidelines for antithrombotic management in this surgical population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.